Study summary · research use only
A potentially effective drug for patients with recurrent glioma: sermorelin
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used transcriptome sequencing and clinical data from 1,018 glioma patients (species not specified) to screen for drugs associated with recurrent glioma, using calculated Drug Resistant Scores across 4,865 drugs. The discovery cohort included 325 patients (229 primary, 92 recurrent) and the validation cohort included 693 patients (422 primary, 271 relapsed). Analyses were conducted using R language. The authors report that recurrent glioma patients showed the greatest sensitivity to sermorelin in this drug-screening analysis, particularly among patients with high-grade, IDH-wildtype, and 1p/19q non-codeletion status. Gene ontology and KEGG pathway analyses suggested sermorelin may relate to cell cycle blocking, immune system processes, and negative regulation of immune checkpoints and M0 macrophages. Kaplan-Meier analysis indicated the association between sermorelin sensitivity and patient outcome was independent of postoperative adjuvant treatment.
Abstract
Treatment insensitivity is the main cause of glioma. This study was designed to screen out effective drugs for recurrent gliomas based on the transcriptomics data. A total of 1,018 glioma patients with transcriptome sequencing data and clinical data were included in this study. There were 325 patients in the discovery cohort, including 229 primary patients and 92 recurrent patients. There were 693 patients in the validation cohort, including 422 primary patients and 271 relapsed patients. Drug Resistant Scores (DRS) of 4,865 drugs of each patient were used for screening. The analysis and drawing in this study were mainly based on R language. After high-throughput drug screening, we found that recurrent glioma patients were most sensitive to sermorelin. Further analysis revealed that sermorelin was suitable for recurrent patients with high grade, IDH-wildtype and 1p/19q non-codeletion status. GO and KEGG analyses found that sermorelin may inhibit tumor cell proliferation by cell cycle blocking. Moreover, sermorelin was also related to the immune system process and negatively regulated immune checkpoints and M0 macrophages. Lastly, the Kaplan-Meier method showed the patient's benefit from sermorelin was independent of postoperative adjuvant treatment. Recurrent glioma patients are sensitive to sermorelin and it makes effect through glioma cells proliferation inhibiting and immune response enhancing.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.